Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/129860
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorAgirre, Mireiaes_ES
dc.contributor.authorOjeda, Edilbertoes_ES
dc.contributor.authorZárate, Jones_ES
dc.contributor.authorPuras, Gustavoes_ES
dc.contributor.authorGrijalvo, Santiagoes_ES
dc.contributor.authorGarcía Del Caño, Gontzales_ES
dc.contributor.authorEritja Casadellà, Ramónes_ES
dc.contributor.authorBarrondo, Sergioes_ES
dc.contributor.authorGonzález-Burguera, Imanoles_ES
dc.contributor.authorLópez De Jesús, Maideres_ES
dc.contributor.authorSallés, Joanes_ES
dc.contributor.authorPedraz, José Luíses_ES
dc.date.accessioned2016-03-08T08:36:58Z-
dc.date.available2016-03-08T08:36:58Z-
dc.date.issued2015-09-25-
dc.identifier.citationMolecular Pharmaceuticses_ES
dc.identifier.urihttp://hdl.handle.net/10261/129860-
dc.description.abstractThe transfection of human NTera2/D1 teratocarcinoma-derived cell line (or NT2 cells) represents a promising strategy for the delivery of exogenous proteins or biological agents into the central nervous system (CNS). The development of suitable nonviral vectors with high transfection efficiencies requires a profound knowledge of the whole transfection process. In this work, we elaborated and characterized in terms of size and zeta potential three different nonviral vectors: lipoplexes (144 nm; -29.13 mV), nioplexes (142.5 nm; +35.4 mV), and polyplexes (294.8 nm; +15.1 mV). We compared the transfection efficiency, cellular uptake, and intracellular trafficking of the three vectors in NT2 cell line. Lipoplexes exhibited the highest percentages of EGFP positive cells. The values obtained with polyplexes were lower compared to lipoplexes but higher than the percentages obtained with nioplexes. Cellular uptake results had a clear correlation with respect to the corresponding transfection efficiencies. Regarding the endocytosis mechanism, lipoplexes enter in the cell, mainly, via clathrin-mediated endocytosis (CME) while polyplexes via caveolae-mediated endocytosis (CvME). Nioplexes were discarded for this experiment due to their low cellular uptake. By simulating an artificial endosome, we demonstrated that the vectors were able to release the DNA cargo once inside the late endosome. The data collected from this assay showed that at 6 h the genetic material carried by polyplexes was still located in the late endosome, while DNA carried by lipoplexes was already in the nucleus. This result indicates a faster intracellular traffic of the lipid-based vectors. Overall, our work gives new insights into the transfection process of NT2 cells by different nonviral vectors as a first step in the development of ex vivo gene therapy platform.es_ES
dc.description.sponsorshipThis project was partially supported by the University of the Basque Country UPV/EHU (UFI 11/32 and UFI11/35), the Basque Government (Department of Education, GIC-12/150 to J.S, University and Research, for the predoctoral BFI-2011-2226 fellowship, and Department of Industry SAIOTEK S-PE13UN193) and the National Council of Science and Technology (CONACYT, Mexico, Reg. 217101). Technical and human support provided by SGIker (UPV/EHU) is gratefully acknowledged. Authors also wish to thank the intellectual and technical assistance from the ICTS “NANBIOSIS”, more specifically, by the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN) at the University of Basque Country (UPV/EHU).es_ES
dc.language.isoenges_ES
dc.publisherAmerican Chemical Societyes_ES
dc.relation.isversionofPostprintes_ES
dc.rightsopenAccessen_EN
dc.subjectendocytosises_ES
dc.subjectNonviral vectorses_ES
dc.subjectNTera2/D1 cellses_ES
dc.subjectpCMS-EGFPes_ES
dc.subjecttransfectiones_ES
dc.titleNew Insights into Gene Delivery to Human Neuronal Precursor NT2 Cells: A Comparative Study between Lipoplexes, Nioplexes, and Polyplexeses_ES
dc.typeartículoes_ES
dc.identifier.doi10.1021/acs.molpharmaceut.5b00496-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.5b00496es_ES
dc.embargo.terms2016-09-26es_ES
dc.rights.licensehttp://www.sherpa.ac.uk/romeo/issn/1543-8384/es_ES
dc.relation.csices_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.openairetypeartículo-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.languageiso639-1en-
Aparece en las colecciones: (IQAC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Mol_Pharm2015Newinsights.pdf1,02 MBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

SCOPUSTM   
Citations

18
checked on 17-abr-2024

WEB OF SCIENCETM
Citations

15
checked on 24-feb-2024

Page view(s)

251
checked on 18-abr-2024

Download(s)

485
checked on 18-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.